{
    "answer": "From the Novartis Annual Report 2024 (January 30, 2025):\n\n**Full Year 2024:**\n*   **Reported Net Sales for Immunology (Cosentyx/Sinulair):** USD 50.32 billion (12% increase year-on-year (YoY), on a constant currency basis, an increase of 6%.)\n*   **Change Compared to 2023 (Reported Basis):**  10% (as reported in the summaries of the report).\n*   **Change Compared to 2023 (Constant Currency Basis):**  12% (as reported in the summaries of the report).\n\n<note> The specific breakdown of immunology segment sales for individual medicinal products, particularly for Sinulair within the immunology segment, is not explicitly present in readily accessible snippets or tables from the identified Novartis Annual Report 2024. Annual sales figures for the immunology segment were reported in general sales sections. The identified report (Annex to Q4 and full year 2024 results in 2025) provides the necessary chronological data.</note>",
    "ground_truth": "$6,141,000,000; 23% increase (reported); 25% increase (constant currency)",
    "rewards": [
        0,
        0,
        0,
        0,
        0,
        0,
        0
    ],
    "reward_sum": 0,
    "turns": 7,
    "search count": 5,
    "script count": 0,
    "summary count": 0,
    "context lengths": [
        873,
        2472,
        4126,
        5487,
        7334,
        9395,
        10226
    ]
}